Medical Industry Consolidation Accelerates: Mapix Medical and Yintai Medical Announce Acquisitions on the Same Day

　　【Pharmaceutical Network Industry Dynamics】M&A expansion has become a常态化 path for medical enterprises to expand their operating scale. With the acceleration of industry integration, many medical enterprises are currently speeding up their efforts to optimize resource allocation and improve operational efficiency through mergers and acquisitions.
 

Recently, Medprin announced that the company is planning to issue shares and pay cash to purchase no less than 51% of the equity in Guangzhou Easycess Medical Co., Ltd. ("Easycess Medical"), along with raising supporting funds. According to the announcement, Medprin has signed a letter of intent with major transaction parties such as Zexin Medical and Yichuangxiang, and is expected to disclose the transaction plan within no more than 10 trading days.
 

Public information shows that Guangzhou Easycess Medical Co., Ltd. is a technology-based innovative enterprise integrating the R&D, production, manufacturing, and sales of advanced interventional medical devices, with extensive product portfolios in ischemic stroke treatment, hemorrhagic stroke treatment, and access solutions. The company's business spans 100 cities and 20 countries. Medprin, on the other hand, is a science and technology innovation enterprise focused on high-performance implantable medical devices, offering products such as artificial dura mater (spinal) patches, craniomaxillofacial repair and fixation systems, absorbable regenerated oxidized cellulose, and dural medical glue, covering key implantable medical devices required for craniotomy surgeries.
 

Through this acquisition, Medprin will expand its product portfolio and increase its influence in the medical device field. Data shows that Medprin has currently obtained 10 China medical device registration certificates and MDR certificates for five products, with a market presence covering over 100 countries and regions worldwide. In recent years, with the continuous increase in sales of core products and expanding markets, Medprin's performance has maintained growth. In the first quarter of 2025, the company achieved revenue of 73.7 million yuan, representing a year-on-year increase of 28.84%, and net profit of 24.16 million yuan, reflecting a year-on-year increase of 61.68%.
 

On May 21, INT Medical announced that it had joined hands with a special M&A fund under Shanghai Science and Technology Venture Capital Co., Ltd. ("Shanghai Sci-Tech Investment Fund") to sign a formal acquisition agreement with relevant shareholders of Hangzhou Wei Qiang Medical Technology Co., Ltd. ("Wei Qiang Medical"). The company and Shanghai Sci-Tech Investment Fund plan to acquire more than 81% of Wei Qiang Medical's shares by purchasing existing shares, of which the company intends to obtain a controlling stake of over 51%.
 

According to reports, INT Medical is one of the few medical device manufacturers in China that possesses complete industrial capabilities, including independent mold development, product research and development, equipment development, and autonomous sterilization. To date, the company oversees 22 subsidiaries, each focusing on the research, production, and sales of innovative products across multiple fields such as cardiology, peripheral, neurology, orthopedics, urology, ENT, and non-invasive treatment with high-intensity focused ultrasound.
 

Wei Qiang Medical focuses on the research, development, production, sales, and technical support of peripheral vascular interventional medical devices. The company mainly operates in aortic, venous, lower limb vascular products, and related catheters and balloon products, having obtained 8 NMPA registration certificates. Additionally, it has applied for over 300 patents, including more than 200 invention patents, with several core patents authorized in countries and regions such as China, the United States, and Europe.
 

Since the aortic and peripheral vascular intervention/implantation is one of the important fields in INT Medical's industrial layout, the acquisition of Wei Qiang Medical will help further enhance its product portfolio in the field of aortic and peripheral vascular intervention and implantation, and jointly promote product innovation and clinical application of vascular interventional technology.
 

Overall, many medical companies are currently expanding their business scope and strengthening their product pipelines through mergers and acquisitions. With advancements in technology and changes in market demand, it is expected that there will be even more M&A activities in the future, further driving technological innovation, product development, and growth within the healthcare industry.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.